December 2024 – Page 15

Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials

6 months ago talkbio0Tagged CNS disorder, Metabolic Diseases, Phase 3 trials, REL-1017, Relmada, strategic alternatives

Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

6 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

Belharra Therapeutics Reduces Workforce by 40%, Laying Off 21 Employees

6 months ago talkbio0Tagged Belharra, Drug Discovery, Industry

Belharra Therapeutics, layoffs, workforce reduction, biotech industry, drug discovery

European Commission Approves Novo Holdings’ $16.5B Acquisition of Catalent

6 months ago talkbio0Tagged Acquisition, Catalent, Commission, Drug Industry, European (ethnic group), Holdings

Novo Holdings, Catalent, European Commission, Acquisition, Pharmaceutical Industry

Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy

6 months ago talkbio0Tagged Citryll, Forbion, Inflammatory Disease Therapy, Johnson & Johnson Innovation, Neutrophil Extracellular Traps, Novartis, Series B, venture fund

Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion